Allegro Ophthalmics and Senju Pharma collaborate on vascular eye disease therapies in Japan

USA-based Allegro Ophthalmics and Japan’s Senju Pharmaceutical have entered into a collaboration and license agreement to develop and market Allegro’s Integrin Peptide Therapy in Japan. The companies aim to improve the quality of life for patients worldwide who continue to be at risk of blindness from vascular eye diseases by establishing Integrin Peptide Therapy as the first-in-class treatment targeting integrin with an oligopeptide.

Under the terms of the accord, Senju will acquire the rights to co-develop and market Allegro’s Integrin Peptide Therapy in Japan as an intravitreal injection for vascular eye diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). In exchange, Senju has agreed to pay Allegro an eight-digit upfront license fee, additional development and sales milestone fees and a percentage royalty on net sales.

Marc Kirshbaum, chief operating officer of Allegro, said: “In addition to validating the potential of Integrin Peptide Therapy as an additional treatment option for millions of patients at risk of blindness, this partnership provides Allegro with the capital required to significantly progress its clinical program across multiple indications and phases in the United States.”